Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Abbott offers the world’s leading portfolio of solutions for heart failure therapy. We are dedicated to partnering with healthcare professionals to transform heart failure management and treatment through innovation, integration and investment.

With the CardioMEMS™ HF System, we offer the first and only FDA-approved system for monitoring PA pressure that allows patients and their care team to get ahead of heart failure. The HeartMate™ 3 LVAD is the latest advancement in LVAD therapy, helping thousands of patients with advanced heart failure.¹

In this video, you will learn about heart failure symptoms and options for managing and treating more advanced heart failure.

In this video, you will learn about the CardioMEMS HF System and how it can help patients with advanced heart failure. For more information on CardioMEMS, visit cardiomems.com. Patient resources can be found HERE.

In this video, you will learn about HeartMate 3 LVAD therapy and how it can help patients with advanced heart failure. For more information on HeartMate3 LVAD therapy, visit heartmate3.com. Patient resources are available HERE. 

Connect with us at www.abbott.com,on LinkedIn, on Facebook, and on Twitter @AbbottNews and @AbbottGlobal.

1. Based on clinical trial and device tracking data as of June 1, 2021.

RX Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.

CardioMEMS™ HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS™ HF System Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: infection, arrhythmias, bleeding, hematoma, thrombus, myocardial infarction, transient ischemic attack, stroke, death, and device embolization.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

™ Indicates a trademark of the Abbott group of companies.

© 2021 Abbott. All Rights Reserved.